Oncology

Founded in 1985, the Department of Oncology is one of the earlier centers in China to carry out the diagnosis and treatment of thoracic tumors and multidisciplinary comprehensive treatment of lung cancer, and after more than 30 years of effort, it has developed into a modern research-oriented clinical department with strong technical capabilities, advanced equipment, comprehensive treatment modalities, and an integration of oncology clinical care, scientific research, and teaching.

At present, the Department of Oncology is a clinical key discipline of “highest priority” in Shanghai, a clinical key specialty in Shanghai, the lead institution of the Collaborative Innovation Cluster of the Shanghai Municipal Health Commission, a member institution of the Board of Directors of the International Association for the Study of Lung Cancer, an affiliated unit of the Non-Small Cell Lung Cancer Specialty Committee of the Chinese Society of Clinical Oncology (CSCO), an affiliated unit of the Thoracic Oncology Branch of the China Medical Promotion Association, the lead institution of the China East–West Lung Cancer Research Collaboration Group, and the supporting institution of the Institute of Oncology of Tongji University School of Medicine.

The department’s leading figure is Professor Zhou Caicun. It currently has 43 medical staff, including 8 with senior professional titles and 13 with associate senior professional titles; more than 70% hold doctoral degrees. It currently has 252 beds (4 general wards, 1 special-needs ward, 1 day ward). It has now formed a medical team with a well-structured professional echelon, full of vitality, united, pragmatic, and enterprising, comprising Shanghai Leading Talents, Shanghai Outstanding Academic Discipline Leaders, Shanghai Silver Snake Award recipients, Shanghai Pujiang Talents, Shanghai Shuguang Talents, Shanghai Young Top Talents, Shanghai Medical Rising Stars, and others. The team has always adhered to the principle of “people-oriented, patients first,” fully leveraging its distinctive team-based medical strengths to provide patients with high-quality, efficient, individualized medical services, bringing the treatment effectiveness rate and long-term survival rate of lung cancer patients to advanced international and domestic levels.